GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
February 01, 2023 07:20 ET
|
GreenLight Biosciences
The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase I/II clinical trial is the first step in...
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines
January 09, 2023 07:20 ET
|
GreenLight Biosciences
The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine designEpivax Therapeutics, Inc. will contribute a...
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 09, 2022 17:07 ET
|
GreenLight Biosciences
Working toward clinical trial initiation for COVID vaccine candidate in 2023Shingles vaccine candidate selection planned for 2023 in partnership with Serum Institute of IndiaCalantha™, Colorado potato...
GreenLight Biosciences to Participate in Upcoming Investor Conferences in November
November 07, 2022 11:25 ET
|
GreenLight Biosciences
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to deliver on the potential of RNA to address some of the world’s toughest...
GreenLight Biosciences announces realignment to focus on near-term value drivers
October 12, 2022 06:54 ET
|
GreenLight Biosciences
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for...
GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA
October 05, 2022 09:36 ET
|
GreenLight Biosciences
GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armywormFall armyworm is one of the most destructive insect pests on the planet, causing more...
GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 15, 2022 07:30 ET
|
GreenLight Biosciences
GreenLight raised $108.4 million in private placement led by S2G Ventures with strong participation from existing and new investors with cash expected to fund critical programs through the first half...
GreenLight Biosciences announces $109 million financing
August 12, 2022 07:21 ET
|
GreenLight Biosciences
BOSTON, Aug. 12, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for...
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
August 01, 2022 09:00 ET
|
GreenLight Biosciences
GreenLight’s messenger RNA production process is transferable to large-scale equipment and CMO facilitiesTechnology transfer and scale-up from lab bench to Samsung’s commercial facility was completed...
NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants
July 29, 2022 16:40 ET
|
GreenLight Biosciences
BOSTON, July 29, 2022 (GLOBE NEWSWIRE) -- GreenLight Biosciences has announced a collaboration with the National Institutes of Health (NIH) to develop COVID-19 vaccines that are more broadly...